September 30, 2024 C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies C-Path announced the formation of a new task for under its RDCA-DAP, dedicated to...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 9, 2024 FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...
September 5, 2024 Cystic Fibrosis Therapeutics Development Network Contributes New Data Sets to C-Path’s RDCA-DAP, Advancing CF Research and Treatment Strategies Critical Path Institute (C-Path) today announced the addition of significant new data sets...
August 22, 2024 C-Path Awarded $1.5 Million Grant from Ara Parseghian Medical Research Fund at Notre Dame to Enhance Collaboration in Niemann-Pick Disease Research and Drug Development C-Path is thrilled to announce its CPLD Consortium has been awarded a grant from the Ara Parseghian...
August 22, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer C-Path proudly announced today a $250,000 grant award to Peter Wipf, Ph.D...
August 20, 2024 C-Path Receives Data Transfer from The Champ Foundation Registry C-Path has received its first data transfer of natural history data on single large-scale mitochondrial DNA...
August 20, 2024 C-Path’s RDCA-DAP Announces Strategic Partnership with Vivli to Enhance Clinical Trials Data Sharing for Rare Diseases C-Path today announced a strategic data sharing partnership with Vivli, the nonprofit...
August 13, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project on Antibiotic-Resistant Gram-Negative Bacteria C-Path) Translational Therapeutics Accelerator (TRxA) announced today that Kenneth Keiler...
